Lexicon Pharmaceuticals (LXRX) Treasury Shares (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Treasury Shares for 17 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares fell 45.19% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (down 45.19% YoY), while the FY2025 annual figure was $5.2 million, up 12.39% from the prior year.
• Treasury Shares retreated to $2.8 million in Q1 2026 per LXRX's latest filing, from $5.2 million in the prior quarter.
• Across five years, Treasury Shares topped out at $16.5 million in Q1 2025 and bottomed at $867973.0 in Q4 2023.
• Historically, Treasury Shares has averaged $7.8 million across 5 years, with a median of $5.5 million in 2023.
• Annual changes were most pronounced in 2022 — Treasury Shares slumped 72.59% — and 2024, when it soared 59.97%.
• Lexicon Pharmaceuticals' Treasury Shares stood at $2.1 million in 2022, then soared by 39.98% to $2.9 million in 2023, then jumped by 59.97% to $4.6 million in 2024, then gained by 12.39% to $5.2 million in 2025, then plunged by 45.19% to $2.8 million in 2026.
• Business Quant data shows LXRX's Treasury Shares at $2.8 million in Q1 2026, $5.2 million in Q4 2025, and $5.2 million in Q3 2025.